Bowel cancer is one of the most common cancers occurring in humans. A clinical study involving patients taking supplementation of Eloxatin drug with other chemotherapeutic cancer drug for treatment of bowel cancer has found better prognosis and reduced recurrence in these patients. This study which is called as NICE study has proved a combination of Eloxatin with chemotherapeutic drugs more effective than control group which received only cancer chemotherapeutic drug such as 5-Fluorouracil and Folinic acid.
The study has found combination of Eloxatin with 5-Fluorouracil and Folinic acid more effective in treating early bowel cancer compared to control group. International trials show that adding Eloxatin to the standard chemotherapy combination helps reduce the risk of relapse after surgery by 25%.
Hilary Whitaker, chief executive of Beating Bowel Cancer said, "It's impossible to overstate the importance of this decision by NICE for the thousands of people diagnosed every year with early stage bowel cancer and we want all eligible patients to have access to the best chance of cure and although the final guidance may take some months to be confirmed, patients should start speaking now to their clinicians to ensure that they are offered the option of the most effective treatment for their particular type of bowel cancer."
Dr Harpreet Wasan, medical oncologist at Hammersmith Hospital in London said, "This is a landmark decision by NICE in the treatment of bowel cancer, which will be welcomed by clinicians and patients alike."
Source: BBC News.